Asterias Biotherapeutics Inc (NYSE:AST) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 2,461,720 shares, a decrease of 12.1% from the October 13th total of 2,800,014 shares. Based on an average daily volume of 294,067 shares, the short-interest ratio is presently 8.4 days. Currently, 7.8% of the company’s stock are sold short.

Several institutional investors and hedge funds have recently modified their holdings of AST. State Street Corp lifted its holdings in shares of Asterias Biotherapeutics by 24.1% during the 2nd quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 63,773 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Asterias Biotherapeutics by 13.1% during the 2nd quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 6,714 shares during the last quarter. Family Management Corp lifted its holdings in shares of Asterias Biotherapeutics by 15.6% during the 2nd quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 6,416 shares during the last quarter. Finally, California State Teachers Retirement System raised its stake in Asterias Biotherapeutics by 4.6% in the 2nd quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,100 shares during the last quarter.

Shares of Asterias Biotherapeutics (NYSE:AST) opened at $2.35 on Monday. Asterias Biotherapeutics has a twelve month low of $2.25 and a twelve month high of $5.80.

Asterias Biotherapeutics (NYSE:AST) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $1.25 million.

Several brokerages have recently commented on AST. HC Wainwright set a $12.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a report on Wednesday, August 16th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Tuesday, October 10th.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/short-interest-in-asterias-biotherapeutics-inc-ast-declines-by-12-1/1699106.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.